Management Team
Alexander
Shneider,
Ph.D.
Founder and CEO
Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Vlad
Gabai,
Ph.D.
VP of R&D
Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
Charles
Legg
COO
Over 20 years of successful biotech and big pharma experience ranging from program & portfolio manager at the international pharmaceutical company, Shire Pharmaceuticals, to the first full-time employee of the gene therapy startup, Solid Ventures. Successful projects in molecular diagnostics, drug discovery from early POC to pivotal clinical trials, from commercial launching to global expansion, from early seed funding to two $100MM+ IPOs. Focus on gene therapy and immuno-oncology.
Anatoli Meriin,
Ph.D.
Director
30+ years of R&D experience in the fields of Biochemistry and Cell Biology. 40+ papers over 5,000 references. Past academic appointment: Boston University
Ilya Lapshin
JD
General Counsel
Ricarda Cramer,
MBA
Director of Business Development, EU
Jihad A.
Fakhreddine
Director of Business Development, GCC
Vlad
Zayets-Volshin
Director of Business Development, FSU
